BTIG Reiterates Buy Rating on Boston Scientific
BTIG maintains a positive outlook on Boston Scientific with a $65 price target, a 43.52% upside from the current price.
Key Points
- BTIG analyst Marie Thibault reiterated a buy rating on Boston Scientific, setting a price target of $65 on June 16, 2026.
- BTIG's $65 price target implies 43.52% upside from Boston Scientific Corporation's ($BSX) current $45.29 share price.
- Boston Scientific's stock trades near $46.70 with a market cap of about $69.5 billion and a forward P/E ratio of 12.55.
- Top institutional holders like BlackRock and Vanguard have adjusted their positions, reflecting varied confidence levels in the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG analyst Marie Thibault has reiterated a buy rating on Boston Scientific Corporation (NYSE: BSX) with a price target of $65. This reaffirmation came on June 16, 2026, as part of BTIG's continued positive outlook on the medical device company.
Boston Scientific Corporation Stock Down 3.3%
Shares of NYSE:BSX traded near $46.70 recently. Boston Scientific has a market capitalization of approximately $69.5 billion. The company boasts a forward P/E ratio of 12.55 and a beta of 0.559, suggesting lower volatility compared to the market. The stock's 52-week range has seen a low of $45.99 and a high of $109.50. Its 50-day moving average is $55.91, while the 200-day moving average stands at $82.10. The company's financial health is supported by a current ratio of 1.9 and a quick ratio of 0.98, with a debt-to-equity ratio of 42.25.
$BSX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Boston Scientific reported revenues of $20.61 billion, reflecting a revenue growth of 11.6%. The company achieved a net margin of 17.3% and a return on equity of 14.7%. Earnings per share stood at $2.39. Investors are keeping an eye on the next earnings release, scheduled for July 29, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Other Institutional Activity in Boston Scientific
Several institutional investors have made adjustments to their holdings in Boston Scientific. BlackRock, Inc. trimmed its position by 4.17 million shares, leaving it with 131.8 million shares valued at approximately $8.27 billion. On the other hand, Vanguard Capital Management LLC significantly increased its holdings by 96.4 million shares, now owning about 96.4 million shares worth $6.05 billion. FMR LLC reduced its stake by 23.2 million shares, resulting in a total of 74.2 million shares valued at $4.66 billion. Meanwhile, State Street Corp and JPMorgan Chase & Co increased their positions by 2.14 million and 7.98 million shares, respectively.
Insider Buying and Selling at Boston Scientific Corporation
Recent insider activity at Boston Scientific included several buys. On May 20, 2026, David Habiger purchased 2,250 shares at an average price of $55.92, while Edward Ludwig bought 3,580 shares at $56.68, and Cheryl Pegus acquired 1,770 shares at $56.49. Earlier, on May 19, Habiger added 2,200 shares at $56.95. Ellen Zane also bought 3,800 shares on May 7.
Analysts Set New Price Targets
On June 16, 2026, BTIG reiterated its buy rating on Boston Scientific with a $65 price target. Earlier in the month, Truist Securities maintained a buy rating with a $64 target. Canaccord Genuity also held a buy rating, setting a target of $70. Citigroup and Leerink Partners similarly maintained buy ratings with targets of $70 and $74, respectively. Barclays set a higher target at $89, while Wells Fargo downgraded the stock to hold with a $55 target. The consensus among 30 analysts is a strong buy, with a mean target price of $77.10.
About Boston Scientific Corporation
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, develops and markets medical devices worldwide. The company operates in the MedSurg and Cardiovascular segments, offering products for gastrointestinal, urological, and neurological conditions, as well as cardiac rhythm management and peripheral interventions. Founded in 1979, Boston Scientific is led by CEO Michael F. Mahoney and employs about 59,000 people.
Bottom Line
BTIG's reiterated buy rating and $65 price target reflect confidence in Boston Scientific's growth prospects. With robust earnings and a strong market position, the company remains a key player in the healthcare sector. Institutional investors' varied adjustments to their holdings highlight differing perspectives on the stock's future performance. As always, it's important to remember that analyst ratings and institutional filings are backward-looking and may not reflect the most current market conditions.
Get Boston Scientific Corporation alerts
New 13F filings, insider trades, and analyst moves on $BSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.